Small cell lung cancer

Erica B. Bernhardt, Shadia Jalal

Research output: Chapter in Book/Report/Conference proceedingChapter

10 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is an aggressive cancer of neuroendocrine origin, which is strongly associated with cigarette smoking. Patients typically present with a short duration of symptoms and frequently (60–65 %) with metastatic disease. SCLC is a heterogeneous disease including extremely chemosensitive and chemoresistant clones. For this reason, a high percentage of patients respond to first-line chemotherapy but rapidly succumb to the disease. SCLC is generally divided into two stages, limited and extensive. Standard treatment of limited stage disease includes combination chemotherapy with cisplatin and etoposide for four cycles, thoracic radiation initiated early with the first cycle of chemotherapy, and consideration of prophylactic cranial irradiation (PCI) in the subset of patients with good response. Surgery may play a role in TNM stages I and II. In extensive disease, platinum agents and etoposide, used in combination, are again the first-line standard of care in the USA. However, thoracic radiation therapy is used predominately in patients where local control is important and PCI is of uncertain benefit. Despite these treatments, prognosis remains poor and novel therapies are needed to improve survival in this disease.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Pages301-322
Number of pages22
Volume170
DOIs
StatePublished - 2016

Publication series

NameCancer Treatment and Research
Volume170
ISSN (Print)09273042

Fingerprint

Small Cell Lung Carcinoma
Cranial Irradiation
Etoposide
Thorax
Drug Therapy
Standard of Care
Combination Drug Therapy
Platinum
Cisplatin
Radiotherapy
Therapeutics
Clone Cells
Smoking
Radiation
Survival
Neoplasms

Keywords

  • Chemotherapy
  • Immune therapy
  • Paraneoplastic syndromes
  • Prophylactic cranial irradiation
  • Radiation
  • Small cell lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Bernhardt, E. B., & Jalal, S. (2016). Small cell lung cancer. In Cancer Treatment and Research (Vol. 170, pp. 301-322). (Cancer Treatment and Research; Vol. 170). Kluwer Academic Publishers. https://doi.org/10.1007/978-3-319-40389-2_14

Small cell lung cancer. / Bernhardt, Erica B.; Jalal, Shadia.

Cancer Treatment and Research. Vol. 170 Kluwer Academic Publishers, 2016. p. 301-322 (Cancer Treatment and Research; Vol. 170).

Research output: Chapter in Book/Report/Conference proceedingChapter

Bernhardt, EB & Jalal, S 2016, Small cell lung cancer. in Cancer Treatment and Research. vol. 170, Cancer Treatment and Research, vol. 170, Kluwer Academic Publishers, pp. 301-322. https://doi.org/10.1007/978-3-319-40389-2_14
Bernhardt EB, Jalal S. Small cell lung cancer. In Cancer Treatment and Research. Vol. 170. Kluwer Academic Publishers. 2016. p. 301-322. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-319-40389-2_14
Bernhardt, Erica B. ; Jalal, Shadia. / Small cell lung cancer. Cancer Treatment and Research. Vol. 170 Kluwer Academic Publishers, 2016. pp. 301-322 (Cancer Treatment and Research).
@inbook{7a59e792cc9f44c0b9b33f72534bc8ae,
title = "Small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) is an aggressive cancer of neuroendocrine origin, which is strongly associated with cigarette smoking. Patients typically present with a short duration of symptoms and frequently (60–65 {\%}) with metastatic disease. SCLC is a heterogeneous disease including extremely chemosensitive and chemoresistant clones. For this reason, a high percentage of patients respond to first-line chemotherapy but rapidly succumb to the disease. SCLC is generally divided into two stages, limited and extensive. Standard treatment of limited stage disease includes combination chemotherapy with cisplatin and etoposide for four cycles, thoracic radiation initiated early with the first cycle of chemotherapy, and consideration of prophylactic cranial irradiation (PCI) in the subset of patients with good response. Surgery may play a role in TNM stages I and II. In extensive disease, platinum agents and etoposide, used in combination, are again the first-line standard of care in the USA. However, thoracic radiation therapy is used predominately in patients where local control is important and PCI is of uncertain benefit. Despite these treatments, prognosis remains poor and novel therapies are needed to improve survival in this disease.",
keywords = "Chemotherapy, Immune therapy, Paraneoplastic syndromes, Prophylactic cranial irradiation, Radiation, Small cell lung cancer, Targeted therapy",
author = "Bernhardt, {Erica B.} and Shadia Jalal",
year = "2016",
doi = "10.1007/978-3-319-40389-2_14",
language = "English (US)",
volume = "170",
series = "Cancer Treatment and Research",
publisher = "Kluwer Academic Publishers",
pages = "301--322",
booktitle = "Cancer Treatment and Research",
address = "Netherlands",

}

TY - CHAP

T1 - Small cell lung cancer

AU - Bernhardt, Erica B.

AU - Jalal, Shadia

PY - 2016

Y1 - 2016

N2 - Small cell lung cancer (SCLC) is an aggressive cancer of neuroendocrine origin, which is strongly associated with cigarette smoking. Patients typically present with a short duration of symptoms and frequently (60–65 %) with metastatic disease. SCLC is a heterogeneous disease including extremely chemosensitive and chemoresistant clones. For this reason, a high percentage of patients respond to first-line chemotherapy but rapidly succumb to the disease. SCLC is generally divided into two stages, limited and extensive. Standard treatment of limited stage disease includes combination chemotherapy with cisplatin and etoposide for four cycles, thoracic radiation initiated early with the first cycle of chemotherapy, and consideration of prophylactic cranial irradiation (PCI) in the subset of patients with good response. Surgery may play a role in TNM stages I and II. In extensive disease, platinum agents and etoposide, used in combination, are again the first-line standard of care in the USA. However, thoracic radiation therapy is used predominately in patients where local control is important and PCI is of uncertain benefit. Despite these treatments, prognosis remains poor and novel therapies are needed to improve survival in this disease.

AB - Small cell lung cancer (SCLC) is an aggressive cancer of neuroendocrine origin, which is strongly associated with cigarette smoking. Patients typically present with a short duration of symptoms and frequently (60–65 %) with metastatic disease. SCLC is a heterogeneous disease including extremely chemosensitive and chemoresistant clones. For this reason, a high percentage of patients respond to first-line chemotherapy but rapidly succumb to the disease. SCLC is generally divided into two stages, limited and extensive. Standard treatment of limited stage disease includes combination chemotherapy with cisplatin and etoposide for four cycles, thoracic radiation initiated early with the first cycle of chemotherapy, and consideration of prophylactic cranial irradiation (PCI) in the subset of patients with good response. Surgery may play a role in TNM stages I and II. In extensive disease, platinum agents and etoposide, used in combination, are again the first-line standard of care in the USA. However, thoracic radiation therapy is used predominately in patients where local control is important and PCI is of uncertain benefit. Despite these treatments, prognosis remains poor and novel therapies are needed to improve survival in this disease.

KW - Chemotherapy

KW - Immune therapy

KW - Paraneoplastic syndromes

KW - Prophylactic cranial irradiation

KW - Radiation

KW - Small cell lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84983772866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983772866&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-40389-2_14

DO - 10.1007/978-3-319-40389-2_14

M3 - Chapter

C2 - 27535400

AN - SCOPUS:84983772866

VL - 170

T3 - Cancer Treatment and Research

SP - 301

EP - 322

BT - Cancer Treatment and Research

PB - Kluwer Academic Publishers

ER -